Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Rebouche CJ, et al
Safety risks in the GLP-1 market: an update on weight loss medication, May 2026 Drug shortages and coverage gaps have led to criminal counterfeiters exploiting Americans demand for blockbuster diabetes and weight loss drugs made with semaglutide and tirzepatide
Utilization management tools are intended to balance cost control and access but may still pose barriers for people with a medical necessity to take these drugs
Chao, A
doi: 10.3389/fcvm.2024.1446468 Received 09 June 2024 Accepted 21 November 2024 Published 16 December 2024 Volume 11 - 2024 Edited by Masanori Aikawa, Brigham and Women's Hospital and Harvard Medical School, United States Reviewed by Prabhash Kumar Jha, Brigham and Women's Hospital and Harvard Medical School, United States Satyesh K
The importance of endogenously secreted GLP-1 and GIP for postprandial glucose tolerance and -cell function after roux-en-Y gastric bypass and sleeve gastrectomy surgery
US$ 20.09
US$ 21.86
US$ 24.78
US$ 27.89
US$ 27.21
US$ 26.37
US$ 20.06
US$ 22.20
US$ 22.32
